Caxton Associates LLP Has $342,000 Position in Boston Scientific Corporation $BSX

Caxton Associates LLP cut its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 67.5% during the 1st quarter, Holdings Channel reports. The fund owned 5,445 shares of the medical equipment provider’s stock after selling 11,307 shares during the period. Caxton Associates LLP’s holdings in Boston Scientific were worth $342,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. FWL Investment Management LLC bought a new stake in Boston Scientific in the second quarter valued at $26,000. Swiss RE Ltd. bought a new position in shares of Boston Scientific during the 4th quarter worth about $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the 4th quarter valued at about $26,000. Bangor Savings Bank grew its stake in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd bought a new stake in Boston Scientific in the 1st quarter valued at about $28,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific’s board approved a global restructuring plan expected to generate approximately $500 million in annual cost savings by 2029. Management says the initiative is intended to improve efficiency and support future growth, which may strengthen long-term profitability. Reuters restructuring report
• Positive Sentiment: Investors are positioning ahead of Wednesday’s second-quarter results. Analysts reportedly expect revenue growth of about 5.9%, creating a potential catalyst if Boston Scientific delivers stronger-than-expected sales or guidance. Q2 earnings preview
• Positive Sentiment: The company’s FARAFLEX trial is advancing its pulsed-field ablation program for atrial fibrillation, potentially supporting Boston Scientific’s position in the growing cardiac-rhythm-treatment market. FARAFLEX trial update
• Neutral Sentiment: UBS maintained a Buy rating despite lowering its price target to $74 from $95. Oppenheimer likewise cut its target to $85 but retained an Outperform rating, indicating continued confidence but more cautious valuation assumptions. UBS price-target update
• Negative Sentiment: The restructuring will involve job cuts through 2029 and approximately $700 million in restructuring costs, creating near-term execution, employee-disruption and cash-flow concerns even though the plan promises future savings. Restructuring and job cuts report

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Barclays cut their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. Leerink Partners decreased their price objective on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a report on Thursday, May 28th. Canaccord Genuity Group lowered their target price on Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Royal Bank Of Canada cut their target price on Boston Scientific from $100.00 to $85.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Finally, Daiwa Securities Group lowered shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $78.40.

Boston Scientific Price Performance

BSX stock opened at $46.04 on Wednesday. The company has a market capitalization of $68.44 billion, a P/E ratio of 19.27, a price-to-earnings-growth ratio of 0.87 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The business has a 50-day simple moving average of $46.78 and a two-hundred day simple moving average of $63.10.

Boston Scientific announced that its Board of Directors has approved a stock buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity

In related news, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig purchased 3,580 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 9,800 shares of company stock worth $554,012 over the last 90 days. 0.34% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.